CD34 and acute myeloid leukemia: Furthermore, healthy donor-originated CD34+ bone marrow cells (Fig. 2C and Supplementary Fig. S2B, C) as well as peripheral blood mononuclear cells (Supplementary Fig. S2D) were less sensitive to eIF4A3 chemical inhibition compared to AML cells further pointing towards a possible therapeutic window.